Drospirenone for hormonal substitution treatment

Pharmaceutical composition containing drospirenone together with a pharmaceutically acceptable carrier of excipient, wherein said composition does not contain an estrogen and wherein said drospirenone is in micronized form. Also, there is described a pharmaceutical composition consisting of a number...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LIPP RALPH, HEIL WOLFGANG, HILMANN JURGEN, SCHURMANN ROLF
Format:	Patent
Sprache:	eng ; slo
Schlagworte:	BABY COMFORTERS CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICALPURPOSES DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY DEVICES FOR RECEIVING SPITTLE DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGINGPHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL ORADMINISTERING FORMS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Pharmaceutical composition containing drospirenone together with a pharmaceutically acceptable carrier of excipient, wherein said composition does not contain an estrogen and wherein said drospirenone is in micronized form. Also, there is described a pharmaceutical composition consisting of a number of separately packaged and individually removable dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 days. Use of the composition for the manufacture of a medicament for protecting the endometrium from hyperplasia or cancer. Pharmaceutical composition containing drospirenone together with a pharmaceutically acceptable carrier of excipient, wherein said composition does not contain an estrogen and wherein said drospirenone is in micronized form. Also, there is described a pharmaceutical composition consisting of a number of separately packaged and individually removable dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 days. Use of the composition for the manufacture of a medicament for protecting the endometrium from hyperplasia or cancer.